At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
07630 IMPACT THERAP-B
Closed 11-09 16:08:03
9.465
+0.435
+4.82%
High9.680
Low8.980
Vol4.57M
Open9.085
D1 Closing9.030
Amplitude7.75%
Mkt Cap2.67B
Tradable Cap2.67B
Total Shares282.46M
T/O42.60M
T/O Rate1.62%
Tradable Shares282.46M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
IMPACT Therapeutics Launches On-Market Buyback of Up to HK$100 Million
IMPACT THERAP-B (07630) Presents Latest Clinical Data for Senaparib, Selective PARP1 Inhibitors IMP1734 and IMP1707 in Poster Sessions at 2026 ESMO Congress
Impact Therapeutics and Pharmanovia Announce Positive Chmp Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
IMPACT Therapeutics Inc is a China-based company mainly engaged in biotechnology research and commercialization. The Company is in the commercialization stage. The Company is committed to advancing synthetic lethality (SL)-based precision anti-cancer therapies globally. The Company's independently developed core product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The Company is currently developing product pipeline packages such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.